《美股業績》禮萊藥廠季度銷售遜預期 新冠治療藥進入中期測試
美國禮萊藥廠(Eli Lilly)(LLY.US)公布第二季度業績。季度純利14.12億美元,按年升6%。每股季度攤薄純利1.55美元,經調整後為1.89美元,高於市場預期的1.56美元。季度收益54.99億美元,按年跌2%,差於市場預期的57.6億美元。公司指病人因疫情押後新療情,與及首季客戶囤藥效應消失均影響業績。
公司表示已就與加拿大生物科技公司AbCellera合作研發的新冠治療藥進行中期測試,公司同時與君實生物(01877.HK)合作研發新冠治療藥,該藥在早前測試已證實安全及病人可接受,並將進入下階段研發。公司料全年經調整純利介乎7.2至7.4美元,高於早前預測的介乎6.7至6.9美元。
禮萊股價昨日(30日)跌5.4%報153美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.